Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27626820 | 0.93 | GPR84 (0.54) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL7044746 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| SCHEMBL3657396 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| SCHEMBL27728979 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| Hydrochloric Acid SCHEMBL29209660 | 0.91 | GPR84 (0.52) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL2121622 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| SCHEMBL3727403 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| SCHEMBL6274634 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| SCHEMBL9002551 | 0.91 | GPR84 (0.57) | CA2CA1SLC1A2SLC1A1GPR84 | |
| SCHEMBL2494394 | 0.90 | CA2 (0.60) | CA2CA1MAPK1SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0444482-B1 | Oxetanones | HOFFMANN LA ROCHE (CH) | 1996-01-17 | — | — | EP | claimed |
| US-20260062580-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT | THE PILOT INK CO., LTD. (JP) | 2026-03-05 | — | — | US | disclosed |
| US-12460099-B2 | Reversibly thermochromic composition, reversibly thermochromic microcapsule pigment encapsulating reversibly thermochromic composition, and writing instrument using reversibly thermochromic microcapsule pigment | THE PILOT INK CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| EP-3608386-B1 | REVERSIBLY THERMOCHROMIC COMPOSITION, AND REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT HAVING SAME ENCLOSED THEREIN | PILOT INK CO LTD (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-12123107-B2 | Reversibly thermochromic composite fiber | KABUSHIKI KAISHA PILOT CORPORATION (JP) | 2024-10-22 | — | — | US | disclosed |
| CN-115884987-A | Anti-idiotypic antibodies to anti-GPRC 5D antibodies | 詹森生物科技公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220169919-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT | THE PILOT INK CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950068-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, REVERSIBLE THERMOCHROMIC MICROCAPSULE PIGMENT COMPRISING SAME, AND WRITING INSTRUMENT USING SAME | THE PILOT INK CO., LTD. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20210355608-A1 | REVERSIBLY THERMOCHROMIC COMPOSITE FIBER | THE PILOT INK CO., LTD. (JP) | 2021-11-18 | — | — | US | disclosed |
| US-11060018-B2 | Reversibly thermochromic composition and reversibly thermochromic microcapsule pigment encapsulating the same | THE PILOT INK CO., LTD. (JP) | 2021-07-13 | — | — | US | disclosed |
| EP-1569912-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0873881-B1 | Reversible thermochromic compositions | PILOT INK CO LTD (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-5919404-A | MIXTURE OF COLOR DEVELOPING COMPOUND AND ELECTRON ACCEPTORALKOXYPHENOL COMPOUND | THE PILOT INK CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0873881-A1 | Reversible thermochromic compositions | The Pilot Ink CO., Ltd. (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0444482-B1 | Oxetanones | HOFFMANN LA ROCHE (CH) | 1996-01-17 | — | — | EP | disclosed |
| US-5466708-A | Carbamyloxyoxetanone compounds | HOFFMANN-LA ROCHE INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5376674-A | Lipase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5260310-A | Oxetanone compounds and pharmaceutical compositions containing them | HOFFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0444482-A2 | Oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062580-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT | TYR, SCO2, HBB | CA2 1535/4885CA1 4057/4885MAPK1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.